Milsaperidone is an active metabolite of iloperidone

Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.

The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.

Teens who use weed are twice as likely to develop psychotic or bipolar disorders, a new study says. They also are more likely to have depression and anxiety, researchers reported Feb. 20 in JAMA Health Forum.